Piramal Pharma (NSE:PPLPHARMA) Debt-to-EBITDA : 0.00 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Piramal Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Piramal Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Piramal Pharma's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹12,462 Mil. Piramal Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Piramal Pharma's Debt-to-EBITDA or its related term are showing as below:

NSE:PPLPHARMA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.28 Med: 3.28 Max: 6.3
Current: 3.76

During the past 3 years, the highest Debt-to-EBITDA Ratio of Piramal Pharma was 6.30. The lowest was 0.28. And the median was 3.28.

NSE:PPLPHARMA's Debt-to-EBITDA is ranked worse than
71.54% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs NSE:PPLPHARMA: 3.76

Piramal Pharma Debt-to-EBITDA Historical Data

The historical data trend for Piramal Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Debt-to-EBITDA Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-EBITDA

0.28

3.28

6.30

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial						-	3.74	-	3.40	-

Competitive Comparison of Piramal Pharma's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Piramal Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's Debt-to-EBITDA falls into.

Piramal Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Piramal Pharma's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(21516.2	+	34854.6)	/	8942.5
	=	6.30

Piramal Pharma's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	12462.4
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Piramal Pharma (NSE:PPLPHARMA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Piramal Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma (NSE:PPLPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

543635:India

Address

Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramal.com

Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (NSE:PPLPHARMA) Headlines

No Headlines